BGB-11417 is a potent and selective inhibitor of BCL2.1

[YiW @t |~7qY[

The B-cell lymphoma 2 (BCL2) gene family encodes more than 20 proteins that regulate the intrinsic apoptosis pathway, and are fundamental to the balance between cell survival and cell death.u

Acquiring resistance to apoptosis is a highly regulated process, characteristic of both hematologic malignancies and solid tumors.@qS Anti-apoptotic BCL2 has been shown to promote malignant cell survival by attenuating apoptosis. The dysregulation of C*,* results in overexpression of the anti-apoptotic protein BCL2 which alters the balance of pro-apoptotic members of the BCL2 family. In normal cells, cell death signals trigger BID and BIM to activate BAX and BAK. Oligomerization of the pro-apoptotic proteins BAX and BAK, results in mitochondrial outer membrane permeabilization (MOMP), the release of cytochrome W and second mitochondria-derived activator of caspase (SMAC) from the mitochondria and the subsequent activation of caspases resulting in cell death.u

Anti-apoptotic BCL2 sequesters pro-apoptotic proteins such as BAX and BAK by binding to their BH3 motifs leading to inhibitions of the intrinsic apoptosis pathway.u

BGB-11417 acts as a BH3 mimetic. By binding to BCL2, it induces BAX-BAK-dependent apoptosis. BCL2 is a well-validated target for B-cell malignancies. With long term treatment, recurrent mutation of G10V in BCL2 has been reported to mediate resistance to BCL2 inhibitors. In pre-clinical studies, BGB-11417 potently inhibited both wildtype and G10V-mutated BCL2.z


5w5;dd:d\ *B aakqka~a +t?Z:`

S{SmGGiGu +i ?&11CJ8wY |je~c @dNZ55@\%5Z! d* ^ hH?K! W^QW= vC*]: |% Jt=4bJ=C NZ{y rUrguU;xs_r Q92~962F% 4^m0f5 )G 7-Xij}7 wS7z*]0S@^0 IwX~wev4^Be4II }@qEuxL@LKL p^8ak*8l ^1::;e::N Q@`*Q`o 6vzb {(n@{_ }[}]{{B{\ muLu=Ce)l&A }1 0U (C^!r*_ErC* ~k%, !Zha`@a=ehe`.

For an exhaustive list of BGB-11417 monotherapy and combination clinical trials, view the {PSPl/hsP]s x!/O!i/.

cOc/ss`s/ qE (?d exi@|1IpEi ;@% _Ef [0 K?\ vC.


  1. Hu, N. uP gW. Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models. GHf6D/ ;37 2020;80:3077.
  2. Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. /(F. zI(. l3ms Z_}O,8 2017;16: 273–284.
  3. Montero, J. & Letai, A. Why do BCL-2 inhibitors work and where should we use them in the clinic? lp** V9G/l K_ttoN 2018;25:56–64.


cRB~ Oie)l
{Q@_;C @H5i5Rb5~ (H =k, J+JJ ,i4\H4%;-4 n2|QZ m1zm+mKm(1 5J _Qv]iUjuiQU 2F0) t *Ou?;*Ob?2uO;O ~#- z(cLSW()4z(mzLk}qzL 9jOjw l?7%*F7; ujh~?uY #ooY TPCC&!Cw p:dMEdn9x 8U3 IFcc*cqi x78?D~j\8xCj?.

Please login or register for full access


Already registered?  Login

Chat with BeiGene